Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | The role of the pharmacist in transplant

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the University of Washington Medical Center, Seattle, WA, outlines the many roles pharmacists play for patients undergoing transplants, particularly relating to their pre- and post-transplant drugs.

Transcript (edited for clarity)

Our process, at least at our institution, is that we have teams that we cover. So every patient who comes in for a transplant is on a certain team, which is primarily covered by an advanced practice provider and a nurse, with the pharmacist covering about two to three teams at any given time; we are there for particularly medication management.
So thinking about the considerations about what medications do we need to start transplant patients on, and what medications might we need to stop before the transplant and then think about restarting...

Our process, at least at our institution, is that we have teams that we cover. So every patient who comes in for a transplant is on a certain team, which is primarily covered by an advanced practice provider and a nurse, with the pharmacist covering about two to three teams at any given time; we are there for particularly medication management.
So thinking about the considerations about what medications do we need to start transplant patients on, and what medications might we need to stop before the transplant and then think about restarting. We’re also involved in, not the writing of the chemotherapy, but the checking of the chemotherapy orders and the growth factor orders for mobilization, doing any therapeutic drug monitoring that needs to be done, particularly for immunosuppressants, in our allo transplant patient population as well as things like azole antifungals.
We also look at any drug adjustments that need to be made, in terms of their dose, as it relates to the patient’s organ function, and we do the bisulfan kinetics at our institution. Not every place does; we have a pretty large patient population from across the country that we follow, and then we’re involved too in different committees, including our standard practice committee which helps develop our standard practices, as it says for our transplant processes, and that covers everything from medications to just clinical considerations for non medications using transplants. So we have kind of a big role so we we can expand or contract that role as we see fit the you know those are the basics of what we do.

Read more...